| Bid | 16.5 |
| Market Cap | 607.67M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -58.29 |
| PE Ratio (ttm) | -0.31 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 19.4 |
| Volume | 511,079 |
| Avg. Volume (20D) | 791,924 |
| Open | 18.74 |
| Previous Close | 18.57 |
| Day's Range | 17.85 - 19.33 |
| 52-Week Range | 12.33 - 24.92 |
| Beta | undefined |
About GRAL
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated ...
Analyst Forecast
According to 2 analyst ratings, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $16, which is a decrease of -11.53% from the latest price.
1 month ago · marketwatch.com
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumblesKaren Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.
